# Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia

> **NCT05665387** · PHASE2 · COMPLETED · sponsor: **Santen Inc.** · enrollment: 79 (actual)

## Conditions studied

- Presbyopia

## Interventions

- **DRUG:** 0.1% STN1013600 ophthalmic solution
- **DRUG:** 0.3% STN1013600 ophthalmic solution
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05665387
- **Lead sponsor:** Santen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-22
- **Primary completion:** 2023-07-27
- **Final completion:** 2023-07-27
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2024-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05665387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05665387, "Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT05665387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*